OS - SIRT to BSC

'overall survival for patients receiving 90Y-resin microspheres compared to BSC by a mean of 1.15 life years (2.12 vs. 0.98 years),'

http://annonc.oxfordjournals.org/co...id=1&usestrictdates=yes&resourcetype=HWCIT&ct

'Results: The results show an increase in overall survival for patients receiving 90Y-resin microspheres compared to BSC by a mean of 1.15 life years (2.12 vs. 0.98 years), with a corresponding increase in quality adjusted life years (1.50 vs. 0.70). The associated costs for SIRT and BSC are €48,552 vs. €23,300, respectively. The additional costs are due to the SIRT treatment and the cost associated with extension to life. The cost per QALY is €30,610. Sensitivity analyses show that the model is robust to changes in parameters. Scenario analysis results demonstrate that the cost per QALY is not sensitive to alternative assumptions for survival curves, utilities or progression, varying only between €28,363 and €31,940. The one-way sensitivity analysis found that the parameters that had the biggest effect are those relating to the curve used to model overall survival. The probabilistic sensitivity analysis found that the probability of 90Y-resin microspheres being cost effective at a willingness-to-pay threshold of €33,506/QALY (1xGDP) is 69%..'

Unfortunately I don't see the numbers upon which this data is based, which is very disappointing. However the OS being suggested by this paper shows OS going from 1 year to over 2 years. If the SRX trials replicate this sort of data then it will be SOC at some point.